RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RIGL • US7665597024

34.09 USD
-0.53 (-1.53%)
Last: Feb 11, 2026, 09:35 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall RIGL gets a fundamental rating of 7 out of 10. We evaluated RIGL against 523 industry peers in the Biotechnology industry. While RIGL has a great health rating, its profitability is only average at the moment. RIGL is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make RIGL a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • RIGL had positive earnings in the past year.
  • In the past year RIGL had a positive cash flow from operations.
  • In the past 5 years RIGL reported 4 times negative net income.
  • In multiple years RIGL reported negative operating cash flow during the last 5 years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • The Return On Assets of RIGL (46.72%) is better than 99.43% of its industry peers.
  • RIGL's Return On Equity of 96.34% is amongst the best of the industry. RIGL outperforms 99.43% of its industry peers.
  • With an excellent Return On Invested Capital value of 63.44%, RIGL belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • Looking at the Profit Margin, with a value of 40.17%, RIGL belongs to the top of the industry, outperforming 96.94% of the companies in the same industry.
  • RIGL has a better Operating Margin (42.17%) than 98.85% of its industry peers.
  • RIGL has a Gross Margin of 93.10%. This is amongst the best in the industry. RIGL outperforms 93.69% of its industry peers.
  • In the last couple of years the Gross Margin of RIGL has declined.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
  • RIGL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, RIGL has less shares outstanding
  • The debt/assets ratio for RIGL has been reduced compared to a year ago.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • RIGL has an Altman-Z score of -1.06. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RIGL (-1.06) is comparable to the rest of the industry.
  • The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of RIGL (0.88) is better than 93.88% of its industry peers.
  • A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.25, RIGL is doing worse than 66.16% of the companies in the same industry.
  • Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -1.06
ROIC/WACC4.98
WACC12.73%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.28, RIGL is not doing good in the industry: 72.85% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
  • RIGL's Quick ratio of 2.14 is on the low side compared to the rest of the industry. RIGL is outperformed by 72.08% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 4307.14% over the past year.
  • The Revenue has grown by 79.13% in the past year. This is a very strong growth!
  • Measured over the past years, RIGL shows a very strong growth in Revenue. The Revenue has been growing by 24.77% on average per year.
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%

3.2 Future

  • The Earnings Per Share is expected to grow by 45.43% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 15.70% on average over the next years. This is quite good.
EPS Next Y617.8%
EPS Next 2Y102.8%
EPS Next 3Y73.32%
EPS Next 5Y45.43%
Revenue Next Year68.61%
Revenue Next 2Y26.11%
Revenue Next 3Y22.67%
Revenue Next 5Y15.7%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • RIGL is valuated cheaply with a Price/Earnings ratio of 5.53.
  • RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.04% of the companies in the same industry.
  • RIGL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.03.
  • Based on the Price/Forward Earnings ratio of 8.82, the valuation of RIGL can be described as reasonable.
  • 98.47% of the companies in the same industry are more expensive than RIGL, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.97, RIGL is valued rather cheaply.
Industry RankSector Rank
PE 5.53
Fwd PE 8.82
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaply inside the industry as 99.24% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.66% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.08
EV/EBITDA 3.81
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RIGL may justify a higher PE ratio.
  • RIGL's earnings are expected to grow with 73.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y102.8%
EPS Next 3Y73.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RIGL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (2/11/2026, 9:35:37 AM)

34.09

-0.53 (-1.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-02
Inst Owners85.11%
Inst Owner Change1.65%
Ins Owners2.59%
Ins Owner Change-2.69%
Market Cap618.73M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (40.63%)
Short Float %20.94%
Short Ratio7.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)3.68%
PT rev (3m)22.61%
EPS NQ rev (1m)9.34%
EPS NQ rev (3m)23.62%
EPS NY rev (1m)0.92%
EPS NY rev (3m)19.02%
Revenue NQ rev (1m)2.23%
Revenue NQ rev (3m)3.1%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE 5.53
Fwd PE 8.82
P/S 2.19
P/FCF 9.08
P/OCF 9.08
P/B 5.26
P/tB 6.71
EV/EBITDA 3.81
EPS(TTM)6.17
EY18.1%
EPS(NY)3.87
Fwd EY11.34%
FCF(TTM)3.75
FCFY11.01%
OCF(TTM)3.76
OCFY11.02%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -1.06
F-Score7
WACC12.73%
ROIC/WACC4.98
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y617.8%
EPS Next 2Y102.8%
EPS Next 3Y73.32%
EPS Next 5Y45.43%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year68.61%
Revenue Next 2Y26.11%
Revenue Next 3Y22.67%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.